Vanguard Portfolio Management filed a Schedule 13G with the SEC on October 30, 2026, disclosing beneficial ownership of 5,083,540 shares of Neurocrine Biosciences Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Vanguard Portfolio Management reported beneficial ownership of 5,083,540 shares of Neurocrine Biosciences Inc common stock.
  • Percent of class: The reported holdings represent 5% of the outstanding class, according to the filing.
  • Sole dispositive power: Vanguard Portfolio Management reported sole power to dispose of all 5,083,540 shares.
  • Sole voting power: The filing disclosed sole voting power over only 23,504 shares, with shared voting power reported as 0.
  • Event date: The date of the event requiring this filing was September 30, 2026.
  • Affiliates included: The filing states the reported securities reflect holdings of Vanguard Portfolio Management LLC and affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC.
  • Filing signed by: My Trieu-Gatt, Authorized Signatory, Head of Global Fund Administration, on behalf of Vanguard Portfolio Management.

Vanguard Portfolio Management Discloses 5,083,540 Shares in Neurocrine Biosciences

Vanguard Portfolio Management, organized in Pennsylvania and classified as an investment adviser (type "IA"), submitted a Schedule 13G disclosing its position in Neurocrine Biosciences Inc (NASDAQ:NBIX) as of September 30, 2026. The filing was submitted on October 30, 2026. Neurocrine Biosciences is headquartered at 12780 El Camino Real, San Diego, CA 92130, according to the filing, and the securities are identified by CUSIP number 64125C109.

According to the filing, Vanguard Portfolio Management holds 5,083,540 shares in aggregate, representing 5% of the class. Of those shares, the firm reported sole dispositive power over all 5,083,540 shares and sole voting power over 23,504 shares. Shared voting power and shared dispositive power were each reported as 0. The filing notes that it reflects securities beneficially owned by Vanguard Portfolio Management LLC and its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, consistent with SEC Release No. 34-39538 (January 12, 1998).

The filing further states that "investment companies registered under the Investment Company Act of 1940 and other managed accounts" have the right to receive dividends or proceeds from the sale of the reported securities, and that "no one other person's interest in the securities reported herein is more than 5%." Vanguard Portfolio Management certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Vanguard Portfolio Management filed a Schedule 13G reporting beneficial ownership of 5,083,540 shares, or 5%, of Neurocrine Biosciences Inc common stock as of September 30, 2026, with sole dispositive power over all reported shares and sole voting power over 23,504 shares.